The Health Insurer’s Class-Action Complaint Joins Other Testosterone Treatment Lawsuit Claims Filed By Men Who Used Content They Suffered Blood Clots, Heart Attacks And Other Complications As A Result of Using Testosterone Products.
An Ohio-based health insurer has hit several testosterone manufacturers with a class-action testosterone lawsuit that accuses the companies of duping health insurers into paying billions of dollars for ineffective and unsafe testosterone products that place patients’ lives at risk, Wright & Schulte LLC reports. The testosterone replacement therapy complaint alleges that the companies participated in a “decade-long deceptive marketing scheme” to take the male aging process and turn it into a “curable disease state.” The health insurer further accused testosterone makers of promoting the off-label use of their products to treat such conditions as erectile dysfunction, depression, diabetes and obesity when the U.S. Food and Drug Administration (FDA) only approved testosterone replacement therapy to treat hypogonadism, which is low testosterone levels in men due to an underlying medical condition. The testosterone lawsuit names AbbVie, Actavis Pharma, Auxilium Pharmaceutical, Eli Lilly & Company, Endo Pharmaceuticals Inc., and their subsidiaries as defendants. The health insurer’s 341-page complaint, filed November 5 in the U.S. District Court, Northern District of Illinois, purports to represent all health insurance companies that paid for coverage of such testosterone products as AndroGel, Androderm, Axiron, Fortesta Gel and Testopel. (Case No. 1:2014cv08857)
The firm continues to offer free legal consultations to men who believe they have suffered serious cardiac events such as heart attacks, strokes, pulmonary embolism, deep vein thrombosis, and other serious heart problems after taking testosterone treatment products such as AndroGel, Androderm, Testim and other testosterone therapy drugs. You can contact one of the firms experienced attorneys by calling 1-800-399-0795 or visit www.yourlegalhelp.com.
The insurance company’s allegations of testosterone manufacturers marketing their products despite the risks associated with the drugs are similar to those alleged in more than 200 lawsuits filed in the U.S. District Court, Northern District of Illinois. In June, a panel of federal judges transferred all federally filed testosterone lawsuits to the Northern Illinois federal court U.S. District Judge Matthew F. Kennelly is presiding over the pretrial proceedings for the multidistrict litigation. The lawsuits allege that men who took testosterone replacement products such as Axiron, Fortesta and Testim experienced such side effects as stroke, heart attack, blood clots and death. The testosterone medication lawsuits purport that testosterone manufacturers failed to adequately warn doctors and their patients about the cardiovascular risks linked with using testosterone products such as AndroGel and Androderm. The master case list for the Northern Illinois federal court indicates that there are 259 testosterone cases pending in the multidistrict litigation as of November 17. Court documents indicate that the first bellwether trial for AndroGel manufacturer, AbbVie Inc., is scheduled for October 31, 2016.(In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)
Testosterone treatment lawsuit filings began to increase after the FDA announced in January that it was launching an investigation into all FDA-approved products that treat low testosterone levels in men who have an underlying medical condition causing the hypogonadism. The federal agency began its reassessment of the safety and effectiveness of testosterone products after the publication of two observational studies. The FDA said it reviewed a study published in the November 2013 Journal of the American Medical Association which found that older men who had underlying cardiovascular disease and took low testosterone treatment had a 30 percent increased risk of having a stroke, heart attack or death compared to men who did not take the testosterone replacement therapy. The FDA also reviewed a study published in the PLOS One Journal in January 2014 that showed men over 65 and younger men with a pre-existing heart disease were at a greater risk of having a heart attack within the first 90 days after taking low testosterone drugs for the first time. [fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014] [fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ [plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085805, January 29, 2014]
[jama.jamanetwork.com/article.aspx?articleid=1764051, November 6, 2013]
In June, the FDA required testosterone treatment drug manufacturers to include a general warning on the label of their products about the risk of blood clots in veins as a result of using the drugs. Blood clots in the veins include deep vein thrombosis and pulmonary embolism, according to the FDA. The agency said the new warning is not related to its ongoing investigation into testosterone products which is related to blood clots in the arteries.
[fda.gov/Drugs/DrugSafety/ucm401746.htm, June 19, 2014]
About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free testosterone lawsuit case evaluations are available through yourlegalhelp.com, or call 1-888-399-0795.
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377